Thrust Into A New Fundraising Norm

By Matthew Pillar, Editor, BioProcess Online

By the time Randy Schatzman, Ph.D., was the guest on The Business of Biotech podcast, his company, Bolt Biotherapeutics, already had closed a $93 million Series C round of financing in the early months of the COVID pandemic. The CEO had joined Bolt, which focuses on immuno-oncology drug discovery and development, only a year prior.